Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine

Psychooncology. 2013 Jul;22(7):1674-5. doi: 10.1002/pon.3209. Epub 2012 Oct 12.

Abstract

Background: Clozapine is reserved for overcoming treatment resistance in schizophrenia. Malignancy is common in schizophrenia; however, there is limited evidence available on continuing clozapine with chemotherapy, with both having hematological adverse effects.

Objective: To report a case on the use of granulocyte colony-stimulating factor (G-CSF) in conjunction with clozapine and chemotherapy.

Methods: We searched PubMed for any available information on the use of granulocyte G-CSF with clozapine and chemotherapy. We report the case of a patient with schizophrenia who developed B-cell lymphoma and was treated with chemotherapy consisting of CHOP regimen, rituximab, and methotrexate. He was continued on clozapine and G-CSF.

Results: We did not find any reports on G-CSF use in conjunction with clozapine and chemotherapy. We found case reports and a case series on the use of G-CSF in clozapine rechallenge with clozapine-induced agranulocytosis with mixed results. In our patient on clozapine, the white blood cell counts reduced by chemotherapy, were successfully replenished with the use of filgrastim, a G-CSF.

Conclusions: With risks of psychosis relapse and exacerbation with discontinuing clozapine, the addition of G-CSF could be a useful aid in replenishing white cell counts lost to chemotherapy whilst continuing clozapine. However, further study is needed on this combination.

Keywords: agranulocytosis; chemotherapy; clozapine; filgrastim; granulocyte colony-stimulating factor.

MeSH terms

  • Agranulocytosis / chemically induced
  • Agranulocytosis / drug therapy*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Clozapine / adverse effects*
  • Clozapine / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Prednisone / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Rituximab
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Antipsychotic Agents
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Clozapine
  • Filgrastim
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CHOP protocol